

# STATEMENT OF INTENT

PRIME PI & INSTITUTION INFORMATION <i>(Submitting Institution)</i>	
Prime PI Name	
Prime Institution	
Project Title	

SUBRECIPIENT PI INFORMATION <i>(Cooperating Principal Investigator)</i>			
Subrecipient PI Name		ERA Commons ID	
Phone		Email & Fax	

SUBRECIPIENT INSTITUTION INFORMATION <i>(Cooperating Institution)</i>			
Subrecipient Institution			
Performance Site		Congressional District #	UEI #
Institution has compliant Financial Conflict of Interest (FCOI) Policy?	YES	NO	Please read the information in the <i>Certifications</i> section. If your Institution does NOT have written policy of conflicts of interest consistent with the provisions of 42 CFR Part 50, Subpart F & 45 CFR Subtitle A, Part 94, please initial here: _____

SUBRECIPIENT BUSINESS OFFICIAL INFORMATION <i>(Cooperating Business Official)</i>			
Business Official Name			
Address			
Phone		Email & Fax	

PROJECT INFORMATION						
Project Period			Direct Costs		Total Costs	
			F&A Costs			
Human Subjects	YES	NO	Assurance #		Approval Date or Pending:	
Vertebrate Animals	YES	NO	Assurance #		Approval Date or Pending:	
Human Embryonic Stem Cells	YES	NO	Assurance #		Approval Date or Pending:	
Data Exchange	YES	NO	Select One	From Prime to Subrecipient:	From Subrecipient to Prime:	Both:
Inventions And Patents <i>(For Renewal Applications)</i>	YES	NO	Details			

## CERTIFICATIONS

If the Prime Awarding Sponsor is the NIH and the subrecipient is a foreign institution, then the subrecipient organization agrees to abide by the requirements of the NIH Final Updated Policy Guidance for Subaward/Consortium Written Agreement (NOT-OD-23-182), and will provide access to copies of all lab notebooks, all data, and all documentation that supports the research outcomes as described in the progress report, to the primary recipient with a frequency of no less than once per year, in alignment with the timing requirements for Research Performance Progress Report submission. Such access may be entirely electronic.

In signing below and offering to participate in this research program, the Cooperating Institution certifies that neither they nor their principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from receiving funds from any federal department or agency and are not delinquent on any federal debt; they are in compliance with the Drug Free Workplace Act of 1988; they are in compliance with U.S. Code, Section 1352, restrictions on the use of federal funds for the purpose of lobbying; they have filed annually with the Office of Scientific Integrity a PHS form 6349 governing Misconduct in Science; they have filed with DHHS compliance offices certification forms governing Civil Rights (441), Handicapped Individuals (641), Sex Discrimination (639-A), and Age Discrimination (680); they are in compliance with PHS policy governing Program Income; they have established policies in compliance with 45 CFR Part 46, Subpart A (protection of human subjects); the Animal Welfare Act (PL-89-544 as amended) and the Health Research Exchange Act of 1985 (Public Law 99-158); and that they are in compliance with NIH guidelines regarding human pluripotent stem cell research, transplantation of fetal tissue, recombinant DNA and human gene transfer research, and inclusion of women, children & minorities in research.

The appropriate programmatic and administrative personnel of each institution involved in this grant application are aware of the PHS-NIH consortium grant policies and are prepared to establish the necessary inter-institutional agreements consistent with those policies. In signing below, the Cooperating Institution certifies it has implemented and is enforcing a written policy of conflicts of interest consistent with the provisions of 42 CFR Part 50, Subpart F & 45 CFR Subtitle A, Part 94. If a conflict is identified by the Cooperating Institution during the period of the award contemplated under this agreement, the Cooperating Institution will report to the Prime Awardee the existence of the conflict, including the grant title, PI (if different from the investigator with the financial interest) and the specific method the Cooperating Institution adopts for addressing the conflict (managing, reducing, or eliminating it). The Cooperating Institution will rely on the Prime Awardee to report the existence of the conflict to NIH. **If your Institution does NOT have written policy of conflicts of interest consistent with the provisions of 42 CFR Part 50, Subpart F & 45 CFR Subtitle A, Part 94, please initial the Project Information section above.**

## COOPERATING INSTITUTION BUSINESS OFFICIAL:

\_\_\_\_\_  
Name and Title

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

# STATEMENT OF WORK

---

Please type or copy-and-paste the statement of work in the area below.